CN104470920A - 固态形式的维罗菲尼胆碱盐 - Google Patents

固态形式的维罗菲尼胆碱盐 Download PDF

Info

Publication number
CN104470920A
CN104470920A CN201380035844.3A CN201380035844A CN104470920A CN 104470920 A CN104470920 A CN 104470920A CN 201380035844 A CN201380035844 A CN 201380035844A CN 104470920 A CN104470920 A CN 104470920A
Authority
CN
China
Prior art keywords
vemurafenib
wei luofeini
choline salt
preparation
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380035844.3A
Other languages
English (en)
Chinese (zh)
Inventor
F·莱曼
W·阿尔布雷克特
R·古瑟尔
R·塞利格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of CN104470920A publication Critical patent/CN104470920A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380035844.3A 2012-07-03 2013-07-02 固态形式的维罗菲尼胆碱盐 Pending CN104470920A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261667769P 2012-07-03 2012-07-03
US61/667,769 2012-07-03
PCT/US2013/049082 WO2014008270A1 (en) 2012-07-03 2013-07-02 Solid state form of vemurafenib choline salt

Publications (1)

Publication Number Publication Date
CN104470920A true CN104470920A (zh) 2015-03-25

Family

ID=48794226

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380035844.3A Pending CN104470920A (zh) 2012-07-03 2013-07-02 固态形式的维罗菲尼胆碱盐

Country Status (6)

Country Link
US (2) US9221815B2 (https=)
EP (1) EP2870154A1 (https=)
JP (1) JP2015522037A (https=)
CN (1) CN104470920A (https=)
EA (1) EA201590041A1 (https=)
WO (1) WO2014008270A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028351B1 (ru) 2013-03-14 2017-11-30 Ратиофарм Гмбх Твердые формы гидрохлорида вемурафениба
CZ2013943A3 (cs) * 2013-11-27 2015-06-03 Zentiva, K.S. Krystalické formy vemurafenibu
EP3223817A4 (en) 2014-11-29 2018-05-30 Shilpa Medicare Limited Substantially pure vemurafenib and its salts
EP3072528B1 (en) 2015-03-26 2017-07-05 ratiopharm GmbH Composition comprising vemurafenib and cationic copolymer based on methacrylates
WO2017098336A1 (en) * 2015-12-11 2017-06-15 Laurus Labs Private Limited Novel polymorphs of vemurafenib, process for its preparation and pharmaceutical composition thereof
ES2985944T3 (es) * 2016-06-29 2024-11-07 Halo Life Science Llc Método de preparación de una sal de ellagato de dicolinio de poco olor y otras sales orgánicas de colina de poco olor
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
KR102763004B1 (ko) * 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법
EP3860598B1 (en) 2018-10-03 2023-09-06 Jyväskylän Yliopisto Vemurafenib and salts thereof for use in the treatment of enteroviral infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129570A1 (en) * 2009-05-06 2010-11-11 Plexxikon, Inc. Solid forms of sulfonamides and amino acids
CN102361870A (zh) * 2009-04-03 2012-02-22 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102206216B (zh) 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102361870A (zh) * 2009-04-03 2012-02-22 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途
WO2010129570A1 (en) * 2009-05-06 2010-11-11 Plexxikon, Inc. Solid forms of sulfonamides and amino acids

Also Published As

Publication number Publication date
US20150183779A1 (en) 2015-07-02
US20160068530A1 (en) 2016-03-10
JP2015522037A (ja) 2015-08-03
US9221815B2 (en) 2015-12-29
EA201590041A1 (ru) 2015-04-30
EP2870154A1 (en) 2015-05-13
WO2014008270A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
CN104470920A (zh) 固态形式的维罗菲尼胆碱盐
KR101651288B1 (ko) 4-메틸-ｎ-［3-(4-메틸-이미다졸-1-일)-5-트리플루오로메틸페닐］-3-(4-피리딘-3-일-피리미딘-2-일아미노)벤즈아미드의 결정 형태
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
JP6189299B2 (ja) プリドピジン塩酸塩の新規な多形形態
US9067896B2 (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof
JP5261487B2 (ja) ジヒドロプテリジノン誘導体の結晶形
TWI576343B (zh) ５－氯－ｎ２－（２－異丙氧基－５－甲基－４－六氫吡啶－４－基－苯基）－ｎ４－［２－（丙烷－２－磺醯基）－苯基］－嘧啶－２，４－二胺之結晶型式
CN101970425B (zh) 4-氨基-5-氟-3-[5-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]喹啉-2(1h)-酮乳酸盐的结晶形式和两种溶剂化形式
CN101379064A (zh) 二氢蝶啶酮衍生物的三氢氯酸盐形式及其制备方法
US10640487B2 (en) Solid state forms of Nilotinib salts
US20160354351A1 (en) Solid state forms of vemurafenib hydrochloride
BR112014003146A2 (pt) 3,4-dihidro-1h-[1,8]naftiridinonas substituídas com homopiperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para5 preparação destes e uso
CN106995397A (zh) R‑氨磺必利药用盐、制备方法、晶型及其用途
EP2896623A1 (en) CRYSTAL OF N-[2-({2-[(2S)-2-CYANOPYRROLIDIN-1-YL]-2- OXOETHYL}AMINO)-2-METHYLPROPYL]-2-METHYLPYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXAMIDE
JP7068288B2 (ja) ４－（２－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール－６－イルオキシ）－ｎ－メチルピコリンアミドの結晶形
CN104558034A (zh) 磷酸特地唑胺二钠盐的新晶型及其制备方法
KR20260056135A (ko) 갑상선 안질환 치료를 위한 린시티닙의 결정질염
WO2022224269A1 (en) Co-crystals, salts and solid forms of niraparib
WO2016101912A1 (zh) 一种表皮生长因子受体激酶抑制剂的盐的晶型及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150325